Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Lacks Cancer Center at Saint Mary's Health Care
mi
from
Grand Rapids, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Lacks Cancer Center at Saint Mary's Health Care
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Spectrum Health Hospital - Butterworth Campus
mi
from
Grand Rapids, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Spectrum Health Hospital - Butterworth Campus
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Metro Health Hospital
mi
from
Grand Rapids, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Metro Health Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Holland Community Hospital
mi
from
Holland, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Holland Community Hospital
mi
from
Holland, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Hackley Hospital
mi
from
Muskegon, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Hackley Hospital
mi
from
Muskegon, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Joseph Mercy Oakland
mi
from
Pontiac, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Munson Medical Center
mi
from
Traverse City, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Munson Medical Center
mi
from
Traverse City, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Kansas City
mi
from
Kansas City, MO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. John's Regional Health Center
mi
from
Springfield, MO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Centers of the Northern Rockies - Billings
mi
from
Billings, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Centers of the Northern Rockies - Billings
mi
from
Billings, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Vincent Healthcare
mi
from
Billings, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Vincent Healthcare
mi
from
Billings, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Deaconess Billings Clinic - Downtown
mi
from
Billings, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Deaconess Billings Clinic - Downtown
mi
from
Billings, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. James Community Hospital
mi
from
Butte, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. James Community Hospital
mi
from
Butte, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Big Sky Oncology
mi
from
Great Falls, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Big Sky Oncology
mi
from
Great Falls, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Sletten Regional Cancer Institute at Benefis Healthcare
mi
from
Great Falls, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Sletten Regional Cancer Institute at Benefis Healthcare
mi
from
Great Falls, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Peter's Hospital
mi
from
Helena, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Peter's Hospital
mi
from
Helena, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Kalispell Medical Oncology
mi
from
Kalispell, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Kalispell Medical Oncology
mi
from
Kalispell, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Community Medical Center
mi
from
Missoula, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Community Medical Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Montana Cancer Center
mi
from
Missoula, MT
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Cancer Center at Good Samaritan Hospital
mi
from
Kearney, NE
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Cancer Center at Good Samaritan Hospital
mi
from
Kearney, NE
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Randolph Hospital
mi
from
Asheboro, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Randolph Hospital
mi
from
Asheboro, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Mission Hospitals - Memorial Campus
mi
from
Asheville, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Mission Hospitals - Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
mi
from
Eden, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
mi
from
Eden, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wayne Radiation Oncology
mi
from
Goldsboro, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wayne Radiation Oncology
mi
from
Goldsboro, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Annie Penn Cancer Center
mi
from
Reidsville, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Annie Penn Cancer Center
mi
from
Reidsville, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Rutherford Hospital
mi
from
Rutherfordton, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Rutherford Hospital
mi
from
Rutherfordton, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wilson Medical Center
mi
from
Wilson, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wilson Medical Center
mi
from
Wilson, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Forsyth Regional Cancer Center at Forsyth Medical Center
mi
from
Winston-Salem, NC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Forsyth Regional Cancer Center at Forsyth Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Grandview Hospital
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials